Foamix Pharmaceuticals Ltd Company Profile (NASDAQ:FOMX)

About Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)

Foamix Pharmaceuticals Ltd logoFoamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FOMX
  • CUSIP: N/A
  • Web: www.foamixpharma.com
Capitalization:
  • Market Cap: $168.25 million
  • Outstanding Shares: 37,223,000
Average Prices:
  • 50 Day Moving Avg: $4.48
  • 200 Day Moving Avg: $8.32
  • 52 Week Range: $4.03 - $11.27
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.65
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.71 million
  • Price / Sales: 29.47
  • Book Value: $3.13 per share
  • Price / Book: 1.44
Profitability:
  • EBIDTA: ($39,500,000.00)
  • Net Margins: -554.14%
  • Return on Equity: -22.55%
  • Return on Assets: -21.59%
Debt:
  • Current Ratio: 18.90%
  • Quick Ratio: 18.90%
Misc:
  • Average Volume: 316,992 shs.
  • Beta: 1.62
  • Short Ratio: 8.08
 

Frequently Asked Questions for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)

What is Foamix Pharmaceuticals Ltd's stock symbol?

Foamix Pharmaceuticals Ltd trades on the NASDAQ under the ticker symbol "FOMX."

How were Foamix Pharmaceuticals Ltd's earnings last quarter?

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) posted its quarterly earnings data on Wednesday, August, 10th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.02. The business earned $1.50 million during the quarter, compared to the consensus estimate of $1.10 million. Foamix Pharmaceuticals Ltd had a negative net margin of 554.14% and a negative return on equity of 22.55%. View Foamix Pharmaceuticals Ltd's Earnings History.

Where is Foamix Pharmaceuticals Ltd's stock going? Where will Foamix Pharmaceuticals Ltd's stock price be in 2017?

2 brokerages have issued 1-year price objectives for Foamix Pharmaceuticals Ltd's stock. Their predictions range from $9.00 to $20.00. On average, they anticipate Foamix Pharmaceuticals Ltd's share price to reach $14.50 in the next twelve months. View Analyst Ratings for Foamix Pharmaceuticals Ltd.

Who are some of Foamix Pharmaceuticals Ltd's key competitors?

Who owns Foamix Pharmaceuticals Ltd stock?

Foamix Pharmaceuticals Ltd's stock is owned by many different of retail and institutional investors. Top institutional shareholders include RA Capital Management LLC (4.90%), Perceptive Advisors LLC (3.56%), Tekla Capital Management LLC (2.50%), AXA (2.22%), OppenheimerFunds Inc. (1.48%) and MARSHALL WACE ASIA Ltd (1.19%). View Institutional Ownership Trends for Foamix Pharmaceuticals Ltd.

Who sold Foamix Pharmaceuticals Ltd stock? Who is selling Foamix Pharmaceuticals Ltd stock?

Foamix Pharmaceuticals Ltd's stock was sold by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Driehaus Capital Management LLC, OppenheimerFunds Inc., Bank of New York Mellon Corp, Sphera Funds Management LTD., Menta Capital LLC and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Foamix Pharmaceuticals Ltd.

Who bought Foamix Pharmaceuticals Ltd stock? Who is buying Foamix Pharmaceuticals Ltd stock?

Foamix Pharmaceuticals Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., MARSHALL WACE ASIA Ltd, Jennison Associates LLC, Emory University, AXA, Goldman Sachs Group Inc., Renaissance Technologies LLC and Baird Financial Group Inc.. View Insider Buying and Selling for Foamix Pharmaceuticals Ltd.

How do I buy Foamix Pharmaceuticals Ltd stock?

Shares of Foamix Pharmaceuticals Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Foamix Pharmaceuticals Ltd stock cost?

One share of Foamix Pharmaceuticals Ltd stock can currently be purchased for approximately $4.52.

Analyst Ratings

Consensus Ratings for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.50 (220.80% upside)

Analysts' Ratings History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2017Credit Suisse Group AGLower Price TargetOutperform$22.00 -> $9.00HighView Rating Details
8/13/2016GuggenheimReiterated RatingBuy$10.00 -> $20.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Earnings by Quarter for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Earnings History by Quarter for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017Q416($0.26)($0.31)$1.49 millionViewN/AView Earnings Details
8/10/2016Q216($0.25)($0.27)$1.10 million$1.50 millionViewListenView Earnings Details
5/10/2016Q1($0.23)($0.15)$0.53 million$0.75 millionViewListenView Earnings Details
11/11/2015Q315($0.20)($0.11)$1.50 million$0.02 millionViewListenView Earnings Details
8/19/2015Q215($0.14)($0.18)$1.00 million$0.11 millionViewListenView Earnings Details
5/12/2015Q1($0.12)($0.14)$1.00 million$0.45 millionViewN/AView Earnings Details
4/15/2015($0.12)($0.18)ViewN/AView Earnings Details
11/14/2014Q314($0.07)($0.12)$1.00 million$0.42 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Current Year EPS Consensus Estimate: $-1.59 EPS
Next Year EPS Consensus Estimate: $-0.80 EPS

Dividends

Dividend History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Latest Headlines for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Source:
DateHeadline
americanbankingnews.com logoFoamix Pharmaceuticals Ltd (FOMX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 16 at 10:40 PM
americanbankingnews.com logoFoamix Pharmaceuticals Ltd (FOMX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 14 at 2:36 PM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 10:24 PM
finance.yahoo.com logoInvestor Network: Foamix Pharmaceuticals Ltd. to Host Earnings Call
finance.yahoo.com - May 10 at 9:32 AM
americanbankingnews.com logoZacks Investment Research Lowers Foamix Pharmaceuticals Ltd (FOMX) to Hold
www.americanbankingnews.com - May 9 at 7:30 PM
marketbeat.com logoFoamix reports 1Q loss
marketbeat.com - May 9 at 6:01 PM
finance.yahoo.com logoFoamix Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 9 at 5:08 PM
americanbankingnews.com logoFoamix Pharmaceuticals (FOMX) Receiving Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - May 3 at 9:49 AM
finance.yahoo.com logoFoamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for FMX101 in Moderate to Severe Acne
finance.yahoo.com - May 1 at 5:03 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - April 27 at 5:49 PM
finance.yahoo.com logoFoamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Tuesday, May 10
finance.yahoo.com - April 26 at 8:07 PM
americanbankingnews.com logoFoamix Pharmaceuticals (FOMX) Earns Daily Coverage Optimism Rating of -0.27
www.americanbankingnews.com - April 26 at 11:10 AM
americanbankingnews.com logoFoamix Pharmaceuticals (FOMX) Receives News Impact Rating of -0.14
www.americanbankingnews.com - April 18 at 9:59 AM
americanbankingnews.com logoZacks: Brokerages Expect Foamix Pharmaceuticals Ltd (FOMX) Will Announce Quarterly Sales of $0.00
www.americanbankingnews.com - April 12 at 1:42 PM
americanbankingnews.com logoFoamix Pharmaceuticals Ltd (FOMX) PT Lowered to $9.00 at Credit Suisse Group AG
www.americanbankingnews.com - April 3 at 11:44 AM
investopedia.com logoFoamix Acne Drug Fails Late-Stage Study (FOMX)
www.investopedia.com - March 28 at 9:56 PM
americanbankingnews.com logoCredit Suisse Group AG Lowers Foamix Pharmaceuticals Ltd (FOMX) Price Target to $9.00
www.americanbankingnews.com - March 28 at 10:44 AM
us.rd.yahoo.com logoFoamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
us.rd.yahoo.com - March 27 at 11:40 AM
investopedia.com logoFoamix Acne Drug Fails Late-Stage Study
www.investopedia.com - March 27 at 11:40 AM
seekingalpha.com logoHigh-Potential Pipeline And Sufficient Cash Make Foamix Pharmaceuticals A Solid Buy For 2017
seekingalpha.com - March 23 at 5:46 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
finance.yahoo.com - March 8 at 6:05 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the ROTH Capital Partners 29th Annual Growth Conference
finance.yahoo.com - March 7 at 11:34 AM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the Cowen & Company 37th Annual Healthcare Conference
finance.yahoo.com - February 27 at 7:15 PM
finance.yahoo.com logoFOAMIX PHARMACEUTICALS LTD. Financials
finance.yahoo.com - February 25 at 5:05 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Participate in a Panel Discussion at the Dermatology Innovation Forum
finance.yahoo.com - February 23 at 5:17 PM
seekingalpha.com logoFoamix Pharmaceuticals' (FOMX) CEO Dov Tamarkin on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 22 at 10:34 PM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 22-Feb-17 1:30pm GMT
finance.yahoo.com - February 22 at 10:34 PM
biz.yahoo.com logoQ4 2016 Foamix Pharmaceuticals Ltd Earnings Release - After Market Close
biz.yahoo.com - February 22 at 10:45 AM
finance.yahoo.com logoFoamix Reports Year End 2016 Financial Results and Provides Business Update
finance.yahoo.com - February 22 at 10:45 AM
finance.yahoo.com logoCoverage initiated on Foamix by Credit Suisse
finance.yahoo.com - February 16 at 5:14 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Release Fiscal Year 2016 Financial Results and Host Conference Call & Webcast on Wednesday, February 22
finance.yahoo.com - February 7 at 6:30 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 11:19 AM
finance.yahoo.com logoBlog Coverage Egalet Announced Positive Results from Human Abuse Potential Study of Egalet-002
finance.yahoo.com - December 19 at 9:16 AM
us.rd.yahoo.com logoFoamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101
us.rd.yahoo.com - November 29 at 5:11 PM
us.rd.yahoo.com logoFoamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101
us.rd.yahoo.com - November 29 at 5:11 PM
us.rd.yahoo.com logo8:31 am Foamix has completed patient enrollment according to plan in the Company's two Phase 3 clinical trials to evaluate the efficacy and safety of FMX101; expects to report top-line results in the first half of 2017
us.rd.yahoo.com - November 29 at 5:11 PM
finance.yahoo.com logoFoamix to Host Key Opinion Leader Luncheon for Investors Focused on Dermatology, With a Focus on Acne and Rosacea
finance.yahoo.com - November 29 at 5:11 PM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 16-Nov-16 1:30pm GMT
finance.yahoo.com - November 17 at 8:06 AM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at Jefferies London Healthcare Conference on November 17
finance.yahoo.com - November 10 at 9:31 AM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the 25th Annual Credit Suisse Healthcare Conference on November 7
finance.yahoo.com - November 3 at 8:12 AM
streetinsider.com logoFoamix (FOMX) Prices 6M Ordinary Shares Offering for Proceeds of ~$57M
www.streetinsider.com - September 29 at 10:04 AM
finance.yahoo.com logoCan The Uptrend Continue for Foamix Pharmaceuticals (FOMX)?
finance.yahoo.com - September 21 at 9:19 AM
benzinga.com logoFoamix Announces Positive Topline Results from...
www.benzinga.com - September 17 at 9:46 AM
finance.yahoo.com logoInside the Recent Surge in Biotech ETFs
finance.yahoo.com - September 14 at 5:06 PM
rttnews.com logoHere's Why You Need To Watch FOMX Today...
www.rttnews.com - September 12 at 4:54 PM
finance.yahoo.com logoFoamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam …
finance.yahoo.com - September 12 at 4:54 PM
marketwatch.com logoBiotech ETF gets a lift from Raptor deal, Foamix drug trial
www.marketwatch.com - September 12 at 4:54 PM
finance.yahoo.com logo7:01 am Foamix topline results from phase 2 trial evaluating FMX-103 topical minocycline foam for moderate-to-severe papulopustular rosacea
finance.yahoo.com - September 12 at 9:54 AM
finance.yahoo.com logoFoamix to Present Corporate Overview at the Rodman & Renshaw 18th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:51 AM
zacks.com logoHow Foamix (FOMX) Stock Stands Out in a Strong Industry
www.zacks.com - August 29 at 9:42 AM

Social

Chart

Foamix Pharmaceuticals Ltd (FOMX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff